Skip to content

Arka dosage form of shweta Aparajita roots in management of Primary Hypothyroidism as add on along with Thyroxine.

A Pharmacotherapeutic controlled study to evaluate the Efficacy of Shweta Aparajita root Clitoria ternatea Linn. in Arka dosage form as add on along with Thyroxine in the management of Galganda i.e. Primary Hypothyroidism. - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070645
Enrollment
60
Registered
2024-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

None listed

Sponsors

Dr Jayshree Hadke
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients between the age group of 25-50 years & of any Gender. Patients who are already diagnosed as Primary Hypothyroidism and under Thyroxine medication and within six months of Diagnosis and newly diagnosed cases. Patients who are willing and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Patient suffering from systemic disease like Cardiac Disorder/Diabetes Mellitus/COPD/TB/HIV/HCV/HBsAg Immuno-compromised patients. Pregnancy and lactating mother and Renal insufficiency. Patient who are known case of Congenital Hypothyroidism, Hypopitutarism, Secondary Hypothyroidism, Thyroid, Neoplasia & Progressive cases of Myxedema coma. Any serious medical and psychological condition will be excluded. Malabsorption disorders Concomitant use of drugs such as multivitamins, minerals, phenobarbital, phenytoin, carbamazepine, rifampin, glucocorticoids, warfarin, statins, estrogen, and raloxifene.

Design outcomes

Primary

MeasureTime frame
Zulewski’s scoring ThyQoL Anthropometric measuresTimepoint: Clinical Assessment at baseline and monthly for 3 months. Lab test at base line and at the end of 3 months

Secondary

MeasureTime frame
Free T3 Free T4 TSH Evaluation of TolerabilityTimepoint: Clinical Assessment at baseline and monthly for 3 months. Lab test at base line and at the end of 3 months

Countries

India

Contacts

Public ContactDr Jayshree Hadke

Dr D.Y. Patil School of Ayurveda, Nerul, Navi Maumbai

shraddha.nayak@dypatil.edu9619016727

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026